Andere Sprachen Antengene Corporation Limited

Aktien

A2QHCZ

KYG039571008

6996

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:09:00 03.05.2024			% 5 Tage	% 1. Jan.
1.06 ^HKD	0.00%		+13.98%	-47.00%

02.05.	Antengene verzeichnet trotz Umsatzrückgang geringeren Verlust im Jahr 2023	MT
22.03.	Antengene Corporation Limited meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop	02.05.
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024	26.04.
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress across First-in-Class, Best-in-Class Pipeline	25.03.
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22.03.
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study	20.03.
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms	07.03.
Antengene Announces Inclusion of XPOVIO in 2023 China's National Reimbursement Drug List	15.12.
Antengene's Myeloma Medication Included in China's National Reimbursement Drug List	14.12.
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List	14.12.
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance	13.12.
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	11.12.
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	11.12.
Antengene Announces XPOVIO Regulatory Approval in Macau for the Treatment of Relapsed and or Refractory Multiple Myeloma	07.12.
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma	06.12.
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	06.12.
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	20.11.
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	17.11.
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	17.11.
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs	08.11.
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Antengene Corporation Limited

Aktien

A2QHCZ

KYG039571008

6996

Andere Sprachen

Filter